Z. Man

机构：Merck & Co., Inc., Rahway, NJ, USA (United States)

发表论文 45 篇 · 总被引 4888 次 · h-index 13

代表论文

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) (2011 · Journal of Bone and Mineral Research · 被引 699)
Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension (2011 · Journal of Bone and Mineral Research · 被引 344)
Treatment with Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High Risk (2011 · The Journal of Clinical Endocrinology & Metabolism · 被引 220)
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study (2019 · The Lancet Diabetes & Endocrinology · 被引 172)
The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) (2011 · Bone · 被引 80)
Once-yearly zoledronic acid and days of disability, bed rest, and back pain: Randomized, controlled HORIZON Pivotal Fracture Trial (2010 · Journal of Bone and Mineral Research · 被引 35)